Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Broadwell Pharmaceutical Co., LTD. Welcome you!

Service hotline:+86-431-85639055

博大伟业
imgboxbg

NEWS CENTER

Your current location:
Homepage
/
/
Northeast Digestive Disease Forum 2018

Northeast Digestive Disease Forum 2018

  • Categories:News center
  • Author:
  • Origin:
  • Time of issue:2020-10-09
  • Views:0

(Summary description)

Northeast Digestive Disease Forum 2018

(Summary description)

  • Categories:News center
  • Author:
  • Origin:
  • Time of issue:2020-10-09
  • Views:0
Information

From May 4 to 6, the "northeast Digestive Disease Forum 2018" was successfully held in Changchun, Jilin Province, sponsored by The Digestive Disease Branch of Jilin Medical Association, Medical Quality Control Center of Jilin Gastroenterology, and The Digestive Disease Branch of Changchun Medical Association and hosted by the Third Hospital of China-Japan Friendship Hospital of Jilin UniversityProfessor Wang Jiangbin, President of the conference, member of Gastroenterology Branch of Chinese Medical Association and director of Gastroenterology department of China-Japan Friendship Hospital, Jilin University, delivered the opening speech:

Professor Wang Jiangbin, President of the conference, member of Gastroenterology Branch of Chinese Medical Association and director of Gastroenterology department of China-Japan Friendship Hospital, Jilin University, delivered the opening speech:

Professor Wang Jiangbin delivered a speech

Professor Wang Jiangbin introduced the experts and leaders and was warmly welcomed by the participants.

Major Experts:

Professor Tang Chengwei (Chairman elect, Chinese Medical Association Gastroenterology Branch, Director of Gastroenterology department, West China Hospital, Sichuan University)

Professor Ying Han (Chairman of Internal Medicine Branch of Chinese Medical Association, Vice Chairman of Hepatology Branch of Chinese Medical Association, Vice President of Gastroenterology Branch of The First Hospital of Air Force Military Medical University)

Professor Li Yanqing (Vice Chairman of Gastroenterology Branch of Chinese Medical Association, Chairman of Gastroendoscopy Branch of Shandong Province, Vice President of Qilu Hospital of Shandong University)

Professor Dou Xiaoguang (Vice Chairman of Chinese Medical Association Hepatology Branch, Chairman of Liaoning Provincial Hepatology Branch, Director of Department of Infection, Shengjing Hospital affiliated to China Medical University)

Professor Yuan Yaozong (member of The Gastroenterology Branch of The Chinese Medical Association, editor-in-chief of the Chinese Journal of Consumer Medicine, and director of gastroenterology, Ruijin Hospital affiliated to Shanghai Jiao Tong University)

Co-chairmen:

Professor Guo Xiaozhong (Member of standing Committee of Gastroenterology Branch of Chinese Medical Association, Chairman of Gastroenterology Branch of Liaoning Province, Director of Gastroenterology Department of General Hospital of Shenyang Military Region)

Professor Yang Youlin (member of Gastroenterology Branch of Chinese Medical Association, chairman of Gastroenterology Branch of Heilongjiang Province, Director of Gastroenterology Department of the First Affiliated Hospital of Harbin Medical University)

Professor Zheng Changqing (Chair-elect of Liaoning Provincial Branch of Digestive Diseases, Director of the Second Department of Gastroenterology, Shengjing Hospital affiliated to China Medical University)

Other experts attending the meeting:

Liu Yulan, Lv Nonghua, Xie Weifen, Tian Dean, Zhang Jun, Chen Qikui, Zhang Guoxin, Chen Ping, Zhang Zhiguang, Shi Yongquan, Zuo Xiuli, Wang Yingde, Jiang Chunmeng, Sun Mingjun

Attending leaders:

Xu Shuye, full-time vice President of Jilin Medical Association

Gu Xiuli, Secretary-General of Jilin Medical Association

Professor Zhu Dongdong, vice President of China-Japan Friendship Hospital, Jilin University

Xu Shuye, vice President, Professor Zhu Dongdong and Professor Tang Chengwei delivered speeches respectively, wishing the conference a success. Then the academic conference began.


Professor Qian Jiaming is giving a lecture

 

A meta analysis published in 2017 involving 100,000 people (including Chinese) showed that the Hp infection rate in China was about 55.8 percent. In order to investigate the true infection of Hp in China, a strict epidemiological survey was conducted based on the community. The whole country was divided into 8 regions and 32 points, involving a total of 192 resident committees, each of which investigated 144 people. The results showed that the infection rate of Hp was 21%~56.28%, and the situation was still severe.

Hp eradication is of great significance for the prevention of gastric cancer, but the increase of drug resistance rate brings great challenges to Hp eradication, and bismuth is one of the solutions to deal with this problem. Bismuth agent is one of the mucosal protective agents. There are many available mucosal protective agents clinically. Among them, there is evidence at home and abroad that bismuth agent, ichabette, Rebapat and polypramide zinc can improve the eradication rate of Hp.

Polyprimordial zinc is mainly a chelate of L-carnosine and zinc. It was developed in Japan and has nearly 20 years of clinical experience. In 2012, it was successfully developed and listed by Jilin Great Great Pharmaceutical Co., LTD. In addition to improving the eradication rate of Hp, juprezon is widely used in clinical practice. It can also be used in NSAIds-related ulcers, ESD postoperative ulcers, ulcerative colitis, head and neck radiotherapy oral mucositis, synchronous chemoradiotherapy of small cell lung cancer radiation esophagitis, pressure ulcer bedsores, etc.

In terms of improve Hp eradicate rate, many basic research, according to the results of clustering pury zinc on the one hand, can be directly bactericidal activity, blocking helicobacter pylori engraftment, inhibit urease activity, on the other hand can remove urease and chloramine, inhibiting inflammatory cytokines and oxidation at the same time, which laid the poly pury zinc improve Hp eradicate rate basis. The results of rat studies showed that polyprazine had a unique mucosal protection mechanism, which protected gastric mucosal injury by upregulating the cell protection factor HSP72.

A prospective controlled study in Alimentary Pharmacology and Therapeutics showed that the Hp eradication rate increased from 77% (24/31) to 94% (33/35) with no significant difference in adverse events, such as diarrhea, nausea, vomiting, rash and taste changes. Inspired by this, a prospective, randomized, parallel, controlled, multi-center study led by Peking Union Medical College Hospital and led by Professor Qian Jiaming as the main researcher was carried out in China. The purpose of this study was to evaluate the clinical efficacy of polyprazine combined with triple regimen to improve the eradication rate of Hp, compare the clinical efficacy differences of different doses of polyprazine, and hope to recommend and optimize the clinical eradication program of Hp. 330 patients were included in the study plan and randomly divided into 3 groups (control group: omeprazole + amoxicillin + clarithromycin triad ×2 weeks; Treatment group A: Omeprazole + amoxicillin + clarithromycin + Polyprezon 75mg Bid×2 weeks; Treatment group b: omeprazole + amoxicillin + clarithromycin + poprizine for 150mg Bid×2 weeks). The results showed that the Hp eradication rates in both test group A and test group B were significantly higher than those in the control group, while there was no significant difference between the test groups.


In terms of safety, although the incidence of adverse events was higher in the high-dose group than in the control group and the standard-dose group, no serious adverse events occurred.

The results suggest that:

* As a chelating dosage form of human trace element zinc and carnosine, its application in combination with conventional triple anti-HP therapy can improve the eradication rate of Hp.

* There was no significant difference in the incidence of adverse reactions between triple anti-HP therapy and standard dose of polyprazine and triple anti-HP therapy.

* The adverse reactions of triple anti-HP combined with high-dose polyprazine were higher than those of the standard dose combined with triple anti-HP, but the eradication rate of Hp was not further improved.

Scan the QR code to read on your phone

Jilin Province Great Great Pharmaceutical Co. LTD

Service hotline

+86-431-81158731

CONTACT US

Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD

Liaoyuan Production Base: No. 158 Fortune Road, Liaoyuan Economic Development Zone, Jilin Province

Tel:+86-437-6998023

Changchun R&D Center: No. 3786 Juye Street, Jingyue Development Zone, Changchun City, Jilin Province
Tel:+86-431-81158731(Marketing center)

Tel:+86-431-81158756(Research and development center)

Beijing Office: Room 901, Building F, Kaixuan City, 170 Beiyuan Road, Chaoyang District, Beijing
Tel:+86-10-58236233

Medication consultation, feedback on medication adverse reaction, and user complaint telephone:0437-5029815 

NO PUBLIC

Jilin Province Great Great Pharmaceutical Co. LTD

Scan and follow the official official account

Copyright © Jilin Province Great Great Pharmaceutical Co. LTD        吉ICP备20002630号

Website construction:300.cn Changchun   management     

Jilin Province Great Great Pharmaceutical Co. LTD